The best Clinical Trials newsletters

PulmCCM covers critical care and pulmonary medicine, with critical appraisals of new trials, regulatory developments, and case-based teaching questions. Readers get detailed breakdowns of study design, results, and limitations, plus CME-oriented learning content.

A clinician-researcher's Substack covering oncology trial interpretation, including NATALEE survival data, methodology for combination therapy trials, and statistics teaching. It offers commentary on how to critically read oncology evidence for clinicians and informed readers.

A retired cardiologist and former FDA official documents his personal effort to find a Parkinson's treatment, mixing commentary on recent trial results with his own research history and operational updates on drug development. Readers get a firsthand, detailed view of how a non-specialist approaches PD science and what regulatory and safety steps a potential drug must clear.

A daily-style biopharma newsletter offering commentary on therapeutics, regulatory oversight and clinical trials, organised around weekday themes. Readers get a short, opinionated take on industry developments such as biosimilar choices, regulator priorities and upcoming conference data.

MD Reports, by independent journalist Marianne Demasi, publishes investigations into science and medicine, including vaccine policy, trial conduct and drug evidence. Issues dig into primary documents such as trial protocols, regulatory records and committee minutes, though the sample is heavily framed around a critical stance toward institutions.

Long-form articles on clinical trial operations, covering patient enrollment, site sustainability and where trial research is heading. Draws on conference observations from SCRS 2026 and trend analysis aimed at sponsors, CROs and research sites.

The Signal is a weekly-style briefing on how AI is moving into healthcare, pharma and enterprise decision-making, with each issue pairing a news item with what it means for pharma, medical affairs and market access teams. Readers get concise context on regulation, clinical trials and governance developments, framed around practical implications.

A biotech investing newsletter that publishes weekly AI-generated catalyst scanner reports ranking small-cap stocks by upcoming FDA and clinical events, alongside occasional in-depth sector write-ups. Readers get market context, catalyst dates, and an author's view on competitive landscapes, with position disclosures.

A genomics PhD writes pro-progress commentary arguing against safetyist framings of AI, nuclear power and data centers, and that regulation and clinical trials are the real bottlenecks rather than intelligence. Readers get a contrarian, optimistic take on AI policy and abundance-minded science debates.

Detailed analyses of clinical trial readouts and regulatory milestones in biotech, covering mechanism, patient population, competitive landscape and commercial implications. Readers get investor-oriented assessments of individual drug programs such as tozorakimab, zilganersen and DTX301.

RxTeach publishes pharmacy and clinical education pieces covering clinical trial supply chains, the history of drugs, and tuberculosis treatment for students, patients and professionals. The excerpts are mostly generic explainers with frequent promotional lines about donating profits to scholarships.

A healthcare consultancy's newsletter offering guides on biopharma strategy, covering real-world evidence after drug approval, biomarker-driven trial design, and clinical development plans for investor readiness. The writing is largely promotional and generic, with limited concrete data or original reporting.